Bajaj Healthcare’s stock price surged by 6% following the approval of its Active Pharmaceutical Ingredient (API) site in Gujarat by the Therapeutic Goods Administration (TGA) in Australia. This approval signifies that the site meets the necessary standards set by the TGA for manufacturing APIs. Investors reacted positively to this news, leading to a rise in the company’s stock price.